Technology Transfer Statistics
To view interactive metrics charts, visit the Technology Transfer Metrics webpage.
TECHNOLOGY TRANSFER ACTIVITIES
(NIH, CDC, and FDA)1
Fiscal Year | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Activity | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Invention Disclosures | 352 | 320 | 370 | 292 | 320 | 331 | 303 | 237 | 285 | 253 | 251 | 285 | 251 | 234 |
| New U.S. Patent Applications Filed2 | 147 | 135 | 153 | 196 | 205 | 294 | 184 | 124 | 190 | 124 | 143 | 187 | 164 | 174 |
| Total U.S. Patent Applications Filed | 300 | 303 | 358 | 301 | 284 | 342 | 246 | 180 | 265 | 185 | 204 | 247 | 235 | 229 |
| Issued U.S. Patents | 130 | 122 | 197 | 151 | 152 | 145 | 114 | 180 | 107 | 106 | 196 | 87 | 131 | 85 |
| Executed Licenses3 | 198 | 180 | 222 | 275 | 285 | 328 | 329 | 342 | 359 | 334 | 332 | 273 | 291 | 253 |
| NIH | - | - | - | - | - | 298 | 298 | 313 | 328 | 320 | 301 | 253 | 275 | |
| Exclusive | - | - | - | - | - | 73 | 61 | 79 | 74 | 68 | 47 | 44 | 30 | |
| Exclusive (Patent Commercial) | - | - | - | - | - | 26 | 25 | 33 | 30 | 41 | 20 | 13 | 20 | |
| Nonexclusive | - | - | - | - | - | 225 | 237 | 234 | 254 | 252 | 254 | 209 | 212 | |
| Nonexclusive (Patent Commercial) | - | - | - | - | - | 30 | 27 | 21 | 39 | 21 | 26 | 24 | 13 | |
| CDC | - | - | - | - | - | 30 | 31 | 29 | 31 | 14 | 31 | 20 | 35 | |
| Exclusive | - | - | - | - | - | 3 | 3 | 0 | 4 | 1 | 0 | 2 | 2 | |
| Exclusive (Patent Commercial) | - | - | - | - | - | 2 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | |
| Nonexclusive | - | - | - | - | - | 27 | 28 | 29 | 27 | 13 | 31 | 18 | 28 | |
| Nonexclusive (Patent Commercial) | - | - | - | - | - | 5 | 6 | 5 | 7 | 7 | 3 | 1 | 5 | |
| Royalties ($ in millions) | $111.2 | $116.6 | $137.7 | $147.1 | $137.8 | $135.6 | $110.9 | $78.2 | $63.4 | $122.3 | $704.3 | $639.5 | $210.4 | $1,030.04 |
| Executed CRADAs (NIH Only) | 93 | 77 | 79 | 101 | 115 | 111 | 82 | 88 | 99 | 82 | 92 | 208 | 175 | |
| Standard | 57 | 46 | 45 | 73 | 89 | 93 | 63 | 74 | 58 | 53 | 76 | 109 | 71 | 59 |
| Material | 36 | 31 | 34 | 28 | 26 | 18 | 19 | 14 | 29 | 12 | 15 | 24 | 40 | 19 |
| C-RCA4 | NA | NA | NA | NA | NA | NA | NA | NA | 12 | 10 | 4 | 4 | 7 | 3 |
| Clinical CRADAs5 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | 71 | 57 | 64 |
1 FY 11 through FY 13, metrics reflect aggregated data of NIH and FDA. FY 14 through FY 16, metrics reflect aggregated data of NIH, FDA, and CDC. Starting in FY 17, metrics reflect aggregated data of NIH and CDC, only. For all metrics, there is an exception where it is denoted as NIH only. 2 Patent applications include only the first U.S. patent application for a new disclosure filed in the reporting period (data include CIP filings but not Divisional applications). 3Segmented data not available before FY17. 4New CRADA type added in FY2020. 5New CRADA type added in FY2023. | ||||||||||||||
TECHNOLOGY TRANSFER ACTIVITIES
(NIH and FDA)
| Fiscal Year | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Activity | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 |
| Invention Disclosures | 400 | 403 | 388 | 367 | 419 | 402 | 353 | 340 | 351 |
| New U.S. Patent Application Filed1 | 196 | 199 | 186 | 173 | 178 | 176 | 156 | 147 | 181 |
| Total U.S. Patent Applications Filed | 382 | 396 | 347 | 309 | 354 | 3443 | 300 | 304 | 303 |
| Issued U.S. Patents | 86 | 122 | 66 | 93 | 117 | 88 | 110 | 134 | 131 |
| Executed Licenses | 209 | 276 | 313 | 254 | 264 | 259 | 215 | 2262 | 197 |
| Royalties ($ in millions) | $53.7 | $56.3 | $98.2 | $82.7 | $87.7 | $97.2 | $91.2 | $91.6 | $96.9 |
| Executed CRADAs (NIH Only) | 84 | 87 | 80 | 51 | 44 | 72 | 77 | 66 | 68 |
| Standard | 36 | 43 | 39 | 22 | 23 | 33 | 33 | 39 | 40 |
| Material | 48 | 44 | 41 | 29 | 21 | 39 | 44 | 27 | 28 |
1Patent applications include only the first U.S. patent application for a new disclosure filed in the reporting period (data include CIP filings but not Divisional applications). 2Starting in FY2010, the number does not include administrative amendments that modify executed license agreements to correct or clarify non-substantive terms or obligations. | |||||||||
TECHNOLOGY TRANSFER ACTIVITIES1
(NIH and FDA)
| Fiscal Year | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Activity | 1994 | 1995 | 1996 | 1997 | 1998 | 1999 | 2000 | 2001 | 2002 |
| Invention Disclosures | 307 | 271 | 196 | 268 | 287 | 294 | 330 | 379 | 331 |
| Patent Applications | 171 | 147 | 136 | 148 | 132 | 169 | 189 | 179 | 173 |
| Issued Patents | 96 | 100 | 127 | 152 | 171 | 163 | 120 | 99 | 88 |
| Executed Licenses | 151 | 160 | 184 | 208 | 215 | 204 | 188 | 200 | 231 |
| Royalties ($ in millions) | $18.6 | $19.4 | $27.0 | $35.7 | $39.6 | $44.6 | $52.0 | $46.1 | $51.0 |
| Executed CRADAs (NIH Only) | 31 | 32 | 87 | 153 | 149 | 126 | 109 | 120 | 101 |
| Standard | 31 | 32 | 44 | 32 | 43 | 48 | 34 | 44 | 34 |
| Material | NA | NA | 43 | 121 | 106 | 78 | 75 | 76 | 67 |
| 1Historial data prior to introduction of automated tracking and analysis systems. | |||||||||
TECHNOLOGY TRANSFER ACTIVITIES1
(NIH, CDC, and FDA)
| Fiscal Year | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Activity | 1985 | 1986 | 1987 | 1988 | 1989 | 1990 | 1991 | 1992 | 1993 |
| Invention Disclosures | 116 | 115 | 147 | 205 | 229 | 249 | 240 | 311 | 282 |
| Patent Applications | 66 | 84 | 89 | 136 | 202 | 208 | 202 | 224 | 193 |
| Issued Patents | 36 | 32 | 33 | 37 | 32 | 40 | 50 | 77 | 68 |
| Executed Licenses | 25 | 39 | 36 | 44 | 50 | 43 | 88 | 96 | 99 |
| Royalties ($ in millions) | NA | NA | $4.2 | $5.4 | $4.8 | $5.8 | $13.3 | $10.1 | $13.5 |
| Executed CRADAs (NIH Only) | 1 | 4 | 10 | 20 | 42 | 32 | 26 | 30 | 41 |
| 1 Historical data prior to introduction of automated tracking and analysis systems. | |||||||||